Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

Greenbaum, Evgenia; Furst, Arthur; Kiderman, Alexander; Stewart, Brendon; Levy, Rachel; Schlesinger, M.; Morag, A; Zakay‐Rones, Zichria

doi:10.1016/s0264-410x(01)00396-6

Cited by 39 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 and what we actually obtained when testing sera from recipients of a trivalent intramuscular split vaccine containing A/New Caledonia/20/99 (H1N1). Our results also surpassed those of other trials with nonliving nasal influenza vaccines, 27 although both the size and number of doses in the present study were largely different from previous practices. It appeared, moreover, that quite a few of the present volunteers reached protective HAI-levels after less than four doses.…”

Section: Discussionsupporting

confidence: 47%

A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants

Samdal¹,

Bakke²,

Oftung³

et al. 2005

Human Vaccines

View full text Add to dashboard Cite

Twenty-eight healthy adult volunteers were immunized intranasally with an inactivated whole-virus influenza vaccine based on the strain A/New Caledonia/20/99 (H1N1), either in saline or mixed with formaldehyde-inactivated Bordetella pertussis as a mucosal adjuvant, or in a thixotropic vehicle with mucoadhesive properties. After four doses, all groups of vaccinees developed significant IgG-and IgA-antibody responses, measured by ELISA, in respectively serum and nasal secretions. None of the volunteers had demonstrable hemagglutination inhibition (HAI) antibodies in serum before being immunized, whereas more than 80% of them reached HAI titers > 40, considered protective, after immunizations. In addition, cellular immune responses, measured as significant increases in CD4 + T-cell proliferation and granzyme B-producing cytotoxic T-cells, were detected against the vaccine strain as well as against heterologous virus strains (H3N2). However, no additive effect on these responses could be demonstrated with use of B. pertussis or the thixotropic substance in the present vaccines. It appeared, actually, that the mucoadhesive vehicle containing the thixotropic substance was less efficient than were the two other formulations. An influenza vaccine made as a simple particulate formulation of inactivated virus, and given repeatedly onto the nasal mucosa, may thus be an attractive alternative to currently available vaccines.

show abstract

Section: Discussionsupporting

confidence: 47%

A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants

Samdal¹,

Bakke²,

Oftung³

et al. 2005

Human Vaccines

View full text Add to dashboard Cite

show abstract

“…A cold-adapted, live attenuated nasal influenza virus vaccine was confirmed to be safe and efficacious in humans because of the induction of secretory nasal IgA (sIgA) as well as IFN-γ production by specific CD4+ T-cells, even though only a low specific IgG response in serum was observed [29]. Intranasal vaccination with an inactivated trivalent influenza vaccine was also shown to be effective in humans and was able to induce both mucosal sIgA, as well as serum IgG immunologic responses [30]. It might be of interest to evaluate the efficacy of the rH_EIV vaccine upon intranasal administration of our vectored canine influenza vaccine, since EHV-1 naturally targets the nasal mucosa.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza

Rosas

Walle

Metzger

et al. 2008

Vaccine

View full text Add to dashboard Cite

In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and is closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/ 10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical disease induced by CIV and can significantly reduce spread.

show abstract

“…In an alternative approach, a virosome based influenza vaccine, containing HLT as a mucosal adjuvant, proved to be immunogenic in humans and induced strong specific mucosal and systemic antibody responses (36,37). In another recent study, Greenbaum et al reported the effects of intranasal vaccination with an inactivated trivalent influenza virus vaccine in humans (39). In their study, a single immunization resulted in seroconversion in 40-70% of vaccinees (strain dependent) and an overall shift from non-immune to immune in about 50% of the volunteers.…”

Section: Designing Nasal Vaccinesmentioning

confidence: 99%

Upper Respiratory Tract Immunity

Zuercher¹

2003

Viral Immunology

View full text Add to dashboard Cite

Most viral infections occur via mucosal surfaces like the respiratory, gastrointestinal, or genital epithelium. The mucosal immune system is an important component of the body's defense against such infections and consequently induction of mucosal, in addition to systemic immunity, might improve vaccine efficacy. Several orally administered vaccines, for example, against poliovirus and gastrointestinal bacterial infections, have been developed and are widely used. In contrast, to date most vaccines against respiratory pathogens are applied parenterally and thus do not induce significant mucosal immunity. For the development of effective mucosal vaccines a more profound understanding of the immune mechanisms operative at mucosal surfaces and of the interplay between different mucosal compartments is needed. Moreover, factors like the dose, form of application, and type of mucosal adjuvants are critical to the induction of effective mucosal immunity. This brief review will focus mainly on the nasal route and will summarize some recent findings concerning the function of the mucosal immune system of the upper respiratory tract. Furthermore, routes of cross-immunization between distinct mucosal compartments and how they might be relevant to vaccine development will be addressed. Finally, I will outline critical factors for the rational design of nasal vaccines and in this context highlight some recent preclinical and clinical developments in the field.

show abstract

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

Cited by 39 publications

References 42 publications

A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants

A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza

Upper Respiratory Tract Immunity

Contact Info

Product

Resources

About